

Search this document by using the 'Find' command. Press 'Ctrl' + 'F' on your keyboard


Recommendations on the use of medication, developed by the WSCCG – WSFT Joint Medicines Optimisation Group and approved by the Suffolk Clinical Oversight Group and WSCCG Executive



A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
-----	--	----------	--	------------	-----------	--------	--	-------------------




Click below for:

- [→Traffic Light rating explained](#)
- [→Prescriber rating explained](#)
- [→Useful links](#)


A	Acclidinium bromide (Eklira Genuair®)	Primary Care		<i>For the treatment of chronic obstructive pulmonary disease (COPD) - 2nd line (for patients who cannot use the tiotropium device effectively).</i>	<u><i>i</i></u>			Judgement reserved
	Aflibercept	Hospital only		<i>For treating wet age-related macular degeneration.</i>			N (TA294)	
	Agomelatine (Valdoxan®)	No prescribing		<i>For the treatment of major depressive episodes (terminated appraisal).</i>	<u><i>i</i></u>	⚠	N (TA231) Terminated Appraisal	Judgement reserved
	Aliskiren hemifumarate (Rasilez®)	No prescribing		<i>Hypertension</i>		⚠		Not acceptable
	Alitretinoin (Toctino®)	Hospital only		<i>For the treatment of severe chronic hand eczema.</i>	<u><i>i</i></u>		N (TA177)	Judgement reserved
	Alogliptin (Vipidia®)	Primary Care		<i>Type 2 diabetes mellitus</i>	<u><i>i</i></u>		N (NG28)	
	Alprostadil			See erectile dysfunction				
	Amiodarone (Cordarone®)	Hospital initiated/recommended		<i>Antiarrhythmia</i>				
	Amlodipine & valsartan (Exforge®)	Primary Care		<i>Expected to be for use as an antihypertensive in patients whose BP is not adequately controlled on amlodipine or valsartan monotherapy and as replacement for patients taking amlodipine and valsartan.</i>	<u><i>i</i></u>			Nothing new

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Anagrelide (Xagrid® ▼)	Hospital only		Essential thrombocythaemia, within clinical trials.				
	Anakinra (Kineret®)	Hospital only		Rheumatoid arthritis. The management of rheumatoid arthritis in adults.	<u><i>i</i></u>		N (CG79)	
	Anti-cancer drugs including ORAL treatments	Hospital only		Chemotherapy.	<u><i>i</i></u>			
	Anti-nauseants in chemotherapy	Hospital only		Chemotherapy induced nausea.				
	Antipsychotics - depot injections	Hospital initiated/recommended		Schizophrenia (administration by CPNs) see also entry for risperidone S/R.				
	Anti-TNF drugs	Hospital only		Psoriasis	<u><i>i</i></u>			
	Apixaban	Hospital only		For the prevention of venous thromboembolism after total hip or knee replacement in adults.			N (TA245)	
	Apixaban (Eliquis® ▼)	Primary Care		For preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation.			N (TA275)	
	Apixaban (Eliquis® ▼)	Hospital initiated/recommended		For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism.			N (TA341)	
	Apomorphine sublingual			See erectile dysfunction.	<u><i>i</i></u>			
	Aripiprazole (Abilify®)	Hospital initiated/recommended		TA213: For the treatment of schizophrenia in people aged 15 to 17 years. TA292: For treating moderate to severe manic episodes in adolescents with bipolar 1 disorder.	<u><i>i</i></u> <u><i>i</i></u>		N (TA213) N (TA292)	

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Atomoxetine (Strattera®)	Shared care		For Attention Deficit Hyperactivity Disorder (ADHD) in children, young people and adults.			N (NG87)	
	Atypical neuroleptics	Hospital initiated/recommended		Schizophrenia only (excl. clozapine, see separate entry).				
	Avanafil (Spedra®▼)			See erectile dysfunction.	<i>i</i>			
	Azathioprine	Shared care	Download	For use in rheumatology, gastroenterology and dermatology.				
	Azelastine and fluticasone nasal spray (Dymista®)	Primary Care		Relief of symptoms of moderate–severe perennial allergic rhinitis for patients who have failed to respond to a steroid nasal spray with the addition of an oral antihistamine . Treatment with Dymista® must be reviewed after 3 months and only continued for patients who are benefitting from it.	<i>i</i> <i>i</i>			
	Azilsartan medoxomil (Edarbi®▼)	No prescribing		For the treatment of essential hypertension in adults.	<i>i</i>			Nothing new
B	Becaplermin (Regranex®)	Withdrawn		Diabetic foot ulcers.				
	Beta interferon	No prescribing		Patients not conforming to national MS trial criteria.				
	Beta interferon	Hospital only		Patients conforming to national MS trial criteria.				
	Bexarotene (Targretin®)	Hospital only		See anti-cancer drugs.				
	Bicalutamide (Casodex®)	Hospital initiated/recommended		Early prostatic cancer.	<i>i</i>			
	Brimonidine tartrate gel (Mirvaso®)	No prescribing		For the symptomatic treatment of facial erythema in rosacea in adult patients.	<i>i</i>			

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Brivaracetam Briviact®	Hospital initiated/recommended		As an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation.				
	Busulfan (Myleran®)	Hospital only		Refer to briefing sheet				
C	Canagliflozin (Invokana®▼)	Primary Care		Monotherapy for treating type 2 diabetes mellitus <i>in accordance with the SGLT2i monotherapy checklist</i>	<u><i>i</i></u>		N (TA390)	
	Canagliflozin (Invokana®▼)	Primary Care		Combination therapy for treating type 2 diabetes mellitus.	<u><i>i</i></u>		N (TA315)	
							N (NG28)	
	Cannabis sativa extract (Sativex®)	Hospital only		<i>Pain relief in multiple sclerosis.</i>	<u><i>i</i></u>			
	Capecitabine (Xeloda®)	Hospital only		See anti-cancer drugs.				
	Chlorambucil	Hospital only		See anti-cancer drugs.				
	Ciclosporin	Shared care	Refer to hospital letter	<i>Immunosuppression related to dermatology, rheumatology and gastroenterology; must prescribe by brand name.</i> <i>There is no shared care agreement because the patient number is very low. However, there is a requirement that the hospital specialists initiating the drug treatment will communicate with the patient's GP via a hospital letter regarding prescribing and monitoring</i>				
	Ciclosporin	Shared care	Shared care agreement to be provide by transplant centre	<i>Transplant immunosuppression for patients being prescribed in primary care prior to April 2013</i>				
	Ciclosporin	Hospital only		<i>Transplant immunosuppression for patients initiated after April 2013</i>				

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Ciclosporin 0.1% eye drops (Ikervis®)	Hospital initiated/recommended		For treating severe keratitis in adult patients with dry eye disease	<i>i</i>		N (TA369)	
	Cilostazol (Pletal® ▼)	No prescribing		For the treatment of intermittent claudication in people with peripheral arterial disease.	<i>i</i>		N (TA223)	Possibly helpful
	Cinacalcet (Mimpara®)	Hospital only		Primary hyperparathyroidism or parathyroid carcinoma.	<i>i</i>			Possibly helpful
	Cinacalcet (Mimpara®)	Hospital only		For the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.	<i>i</i>		N (TA117)	Possibly helpful
	Clopidogrel	Hospital initiated/recommended		TA 80: Clopidogrel for the treatment of non-ST-elevation acute coronary syndrome. TA 210: Clopidogrel and dipyridamole for the prevention of acclusive vascular events (TA 210). Prescribe generically.			N (TA80)	
	Clozapine	Hospital only		Schizophrenia				
	Colestevlam (Cholestagel®)	Hospital initiated		Lipid-lowering	<i>i</i>			Possibly helpful
	Collagenase clostridium histolyticum (Xiapex® ▼)	Hospital only		For the treatment of Dupuytren's contracture in adult patients with a palpable cord.	<i>i</i>			Judgement reserved
	Cyclo-oxygenase-2 selective inhibitors	Primary Care		Acute pain	<i>i</i>			
	Cyclophosphamide	Hospital only		See anti-cancer drugs.				
D	Dabigatran (Pradaxa®)	Hospital only		For the prevention of venous thromboembolism after hip or knee replacement surgery in adults.			N (TA157)	Offers an advantage
	Dabigatran (Pradaxa®)	Primary Care		For the prevention of stroke and systemic embolism in atrial fibrillation.			N (TA249)	




A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Dabigatran (Pradaxa®)	Hospital initiated/recommended		For the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism.			N (TA327)	
	Dapagliflozin (Forxiga®▼)	Primary Care		Combination therapy for treating type 2 diabetes mellitus.	<u><i>i</i></u>		N (TA288)	
	Dapagliflozin (Forxiga®▼)	Primary Care		Monotherapy for treating type 2 diabetes mellitus in accordance with the SGLT2i monotherapy checklist	<u><i>i</i></u>		N (NG28)	
	Dapoxetine (Priligy®)	No prescribing		For the treatment of premature ejaculation in adult men aged 18-64 years.	<u><i>i</i></u>		N (TA390)	Nothing new
	Darbepoetin alfa (Aranesp®)	Hospital only		For cancer treatment-induced anaemia.	<u><i>i</i></u>		N (TA142)	
	Darbepoetin alfa (Aranesp®)	Hospital only		Renal patients; treatment of anaemia in adult cancer patients with solid tumours (non-haematological malignancies) receiving chemotherapy.				
	Dasatinib (Sprycel®)	Hospital only		See anti-cancer drugs.				
	Deferasirox (Exjade®▼)	Hospital only		Chronic iron overload.	<u><i>i</i></u>			Offers an advantage
	Degarelix (Firmagon®)	Hospital only		For the treatment of adult male patients with advanced hormone dependant prostate cancer.	<u><i>i</i></u>			Possibly helpful
	Denosumab	Hospital initiated/recommended	 	For the prevention of osteoporotic fractures in postmenopausal women.	<u><i>i</i></u>		N (TA204)	Nothing new
	Dexamfetamine	Shared care		For Attention Deficit Hyperactivity Disorder (ADHD) in children, young people and adults.			N (NG87)	




A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Dexibuprofen (Seractil®)	Primary Care		Symptomatic treatment for the relief of pain and inflammation associated with osteoarthritis. Acute symptomatic treatment of pain during menstrual bleeding (primary dysmenorrhoea). Symptomatic relief of other forms of mild to moderate pain such as muscular-skeletal or dental pain.	<i>i</i>			
	Diclofenac sodium 3% gel (Solaraze®)	Primary Care		Treatment of actinic (solar) keratoses.	<i>i</i>			
	Donepezil (Aricept®)	Hospital initiated/recommended		For the treatment of Alzheimer's disease. Updated NICE TA 217 states that: non-specialists can now prescribe donepezil, galantamine, rivastigmine and memantine, as long as they have taken advice from a clinician who has the necessary knowledge and skills. This includes: • secondary care medical specialists such as psychiatrists, geriatricians and neurologists • other healthcare professionals such as GPs, nurse consultants and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease	<i>i</i>		N (TA217)	
	Dornase alfa (Pulmozyme®)	Shared care	under development	Cystic fibrosis.				
	Dronedarone (Multaq®)	Hospital only		For the treatment of non-permanent atrial fibrillation.	<i>i</i>		N (TA197)	Judgement reserved
	Drotrecogin alfa (activated)	Withdrawn		For severe sepsis (withdrawn).			N (TA84)	
	Drugs for assisted conception except clomiphene	Hospital only		Assisted conception.				
	Dulaglutide (Trulicity®)	Hospital initiated/recommended		Type 2 diabetes mellitus	<i>i</i>		N (NG28)	
	Duloxetine (Cymbalta®)	Hospital initiated/recommended		Major depressive episodes.				Possibly helpful

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Duloxetine (Cymbalta®)	Primary Care		Neuropathic pain.	<u><i>i</i></u>			Possibly helpful
	Duloxetine (Yentreve®)	Primary Care		Stress urinary incontinence.	<u><i>i</i></u>			Nothing new
	Duodopa	Hospital only		Parkinson's disease.	<u><i>i</i></u>			Possibly helpful
E	Edoxaban (Lixiana®)	Hospital initiated/recommended		For treating and preventing deep vein thrombosis and pulmonary embolism.			N (TA354)	
	Edoxaban (Lixiana®)	Primary Care		For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation.			N (TA355)	
	Eluxadoline Truberzi®	Hospital only		For the treatment of Irritable Bowel Syndrome (IBS) with diarrhoea	<u><i>i</i></u>		N (TA471)	
	Empagliflozin (Jardiance®▼)	Primary Care		Monotherapy for treating type 2 diabetes mellitus <i>in accordance with the SGLT2i monotherapy checklist</i>	<u><i>i</i></u>		N (TA390)	
	Empagliflozin (Jardiance®▼)	Primary Care		Combination therapy for treating type 2 diabetes mellitus.	<u><i>i</i></u>		N (TA336)	
							N (NG28)	
	Eplerenone (Inspra®)	Hospital initiated/recommended		Left ventricular dysfunction following myocardial infarct.	<u><i>i</i></u>			Possibly helpful
	Erectile dysfunction excluding generic sildenafil, and excluding tadalafil (Cialis®) once daily tablets	No prescribing		Patients not covered by the Health Service Circular (HSC) (see HSC 1999/177 for full description)				
	Erectile dysfunction excluding generic sildenafil, and excluding tadalafil (Cialis®) once daily tablets	Hospital only		Patients with "severe distress".				



A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Erectile dysfunction excluding generic sildenafil, and excluding tadalafil (Cialis®) once daily tablets	Primary Care		<i>Patients covered by the Health Service Circular 1999/177 for this category (see also drug tariff part XVIII B)</i>				
	Generic sildenafil	Primary Care		<i>Erectile dysfunction</i>				
	Tadalafil (Cialis®) 2.5mg and 5mg tablets taken once daily	Hospital initiated/recommended		<i>Treating erectile dysfunction following nerve-sparing radical prostatectomy or external beam radiotherapy for prostate cancer.</i>	<i><u>i</u></i>			
	Tadalafil (Cialis®) 2.5mg and 5mg tablets taken once daily	No prescribing		<i>Treating erectile dysfunction for all indications (other than following nerve-sparing radical prostatectomy or external beam radiotherapy for prostate cancer, as above)</i>	<i><u>i</u></i>			
	Erlotinib (Tarceva®)	Hospital only		See anti-cancer drugs.				
	Erythropoietins	No prescribing		Tumours ; all indications.				
	Erythropoietins	Hospital only		Renal patients ; all indications.				
	Escitalopram (Ciprallex®)	Hospital initiated/recommended		<i>Generalised anxiety disorder.</i>	<i><u>i</u></i>			Possibly helpful
	Estramustine (Estracyt®)	Hospital only		See anti-cancer drugs.				
	Etanercept (Enbrel®)	Hospital only		<i>Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis.</i>			N (TA130)	
	Etanercept (Enbrel®)	Hospital only		<i>Adalimumab, etanercept, infliximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor.</i>			N (TA36)	
	Etanercept (Enbrel®)	Hospital only		<i>For ankylosing spondylitis.</i>			N (TA143)	
	Etanercept (Enbrel®)	Hospital only		<i>For the treatment of juvenile idiopathic arthritis.</i>			N (TA35)	






A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Etoposide	Hospital only		See anti-cancer drugs.				
	Exenatide (Byetta®)	Hospital initiated/recommended		Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes.			N (CG 66 & 87)	Judgement reserved
	Exenatide long acting (Bydureon®)	Hospital initiated/recommended		In combination with oral antidiabetic therapy for the treatment of type 2 diabetes.			N (TA248)	
	Ezetimibe (Ezetrol®)	Primary Care		Primary heterozygous-familial and non-familial hypercholesterolaemia in accordance with the ezetimibe checklist	<u><i>i</i></u>		N (TA385)	
E	Fampridine (Fampyra®▼)	No prescribing		For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).	<u><i>i</i></u>			Judgement reserved
	Febuxostat (Adenuric®)	Primary Care		For the management of hyperuricaemia in people with gout.	<u><i>i</i></u>		N (TA164)	Possibly helpful
	Fentanyl immediate release preparations	Hospital initiated/recommended		Management of breakthrough pain for chronic cancer pain.	<u><i>i</i></u>			Possibly helpful
	Fesoterodine (Toviaz®)	Primary Care		Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in adults with overactive bladder syndrome.	<u><i>i</i></u>			Nothing new
	Fidaxomicin (Dificlr®▼)	Hospital initiated/recommended		Treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults (third line after metronidazole and vancomycin; following a recommendation from a microbiologist- this may be verbal if patients are in the community).	<u><i>i</i></u>			Possibly helpful
	Fingolimod (Gilenya®▼)	Hospital only		For the treatment of highly active relapsing–remitting multiple sclerosis.			N (TA254)	Judgement reserved
	Fluticasone/vilanterol (Relvar Ellipta®▼)	Hospital only		COPD	<u><i>i</i></u>			Not assessed
	Fluticasone/vilanterol (Relvar Ellipta®▼)	Hospital only		Asthma	<u><i>i</i></u>			Judgement reserved
	Fludarabine (Fludara®)	Hospital only		See anti-cancer drugs.				

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Fluorouracil (excluding topical preparations)	Hospital only		See anti-cancer drugs.				
	Fulvestrant (Faslodex®)	Hospital only		See anti-cancer drugs.				
IG	Galantamine	Hospital initiated/recommended		<p>For the treatment of Alzheimer's disease.</p> <p>Updated NICE TA 217 states that: non-specialists can now prescribe donepezil, galantamine, rivastigmine and memantine, as long as they have taken advice from a clinician who has the necessary knowledge and skills. This includes:</p> <ul style="list-style-type: none"> • secondary care medical specialists such as psychiatrists, geriatricians and neurologists • other healthcare professionals such as GPs, nurse consultants and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease 	<i>i</i>		N (TA217)	
							N (CG42)	
	Ganciclovir	Hospital only		CMV retinitis AIDS patients.				
	Gliclazide MR (Diamicon®)	Primary Care		Non insulin-dependent diabetes in adults where dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.	<i>i</i>			
	Glucosamine including combination products	No prescribing		Osteoarthritis: Care and management in adults.			N (CG177)	Not acceptable
	Glycopyrronium bromide - inhaled ▼ (Seebri®)	Primary Care		Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	<i>i</i>			Possibly helpful
	Gold (Myocrisin® injection)	Shared care	under development	Rheumatoid arthritis and other collagen diseases.				
	Gonadorelin analogues	Hospital only		Endometrial thinning prior to surgery.				
	Gonadorelin analogues	Shared care		Prostatic carcinoma.				
	Granulocyte colony stimulating factors	Hospital only		Neutropenia/progenitor cell transplantation.				







A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
H	Grazax	Hospital only		Treatment of moderate to severe seasonal allergic rhinitis.	<i>i</i>			A real advance
	Growth Hormone	Shared care		In adults with growth hormone deficiency.				
	Growth Hormone	Shared care		For the treatment of growth failure in children.			N (TA188)	
	Guanfacine	Shared care		For Attention Deficit Hyperactivity Disorder (ADHD) in children, young people and adults.			N (NG87)	
	HIV therapy	Hospital only		All HIV therapy.				
HRT implants		Withdrawn		Hormone replacement therapy.				
	Hydrocortisone modified release (Plenadren®)	No prescribing		Treatment of adrenal insufficiency in adults.	<i>i</i>			Nothing new
I	Hydroxycarbamide	Hospital only		Myeloproliferative disorders needing cytoreduction.	<i>i</i>			
	Hydroxycarbamide (Hydrea®)	Hospital only		See anti-cancer drugs.				
	Hydroxycarbamide	Shared care	 In West Suffolk, this Shared Care Agreement applies only to sickle cell disease	For sickle cell disease	<i>i</i>			
I	Ibandronic acid (Bonviva®)	Primary Care		Osteoporosis.	<i>i</i>			Possibly helpful



A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Idarubicin (Zavedos®)	Hospital only		See anti-cancer drugs.				
	Imatinib (Glivec®)	Hospital only		<i>For chronic myeloid leukaemia.</i>	<i><u>i</u></i>		N (TA70)	
	Imiquimod 3.75% cream (Zyclara®)	No prescribing		<i>Actinic keratosis</i>	<i><u>i</u></i>			
	Indacaterol (Onbrez+Breezhaler®)	Primary Care		<i>Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).</i>	<i><u>i</u></i>			Offers an advantage
	Infliximab (Remicade®)	Hospital only		<i>Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis.</i>			N (TA130)	
	Infliximab (Remicade®)	Hospital only		<i>Adalimumab, etanercept, infliximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor.</i>			N (TA195)	
	Infliximab (Remicade®)	Hospital only		<i>For the treatment of Crohn's disease.</i>			N (TA187)	
	Infliximab (Remicade®)	Hospital only		<i>For sub acute manifestations of ulcerative colitis.</i>			N (TA140)	
	Infliximab (Remicade®)	Hospital only		<i>For acute exacerbations of ulcerative colitis.</i>			N (TA163)	
	Infliximab (Remicade®)	Hospital only		<i>For ankylosing spondylitis.</i>			N (TA143)	
	Infliximab (Remicade®)	Hospital only		<i>For the treatment of adults with psoriasis.</i>			N (TA134)	
	Ingenol (Picato®▼)	Hospital initiated/recommended		<i>Actinic keratosis – one course of treatment only.</i>	<i><u>i</u></i>			Possibly helpful
	Inhaled insulin	Withdrawn		Diabetes				

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Inositol nicotinate (Hexopal®)	No prescribing		<i>For the treatment of intermittent claudication in people with peripheral arterial disease.</i>	<u><i>i</i></u>		N (TA223)	
	Insulin	Hospital initiated/recommended		<i>Diabetes</i>		△		
	Insulin analogues	Hospital initiated/recommended		<i>Diabetes</i>	<u><i>i</i></u>	△		
	Insulin aspart 100 units in 1mL (Fiasp® ▼)	Hospital initiated/recommended		<i>Type 1 and type 2 diabetes.</i>	<u><i>i</i></u>			
	Insulin degludec (Tresiba® ▼)	Hospital initiated/recommended		<i>Type 1 and type 2 diabetes.</i>	<u><i>i</i></u>			Judgement reserved
	Insulin degludec/liraglutide (Xultophy® ▼)	Hospital initiated/recommended		<i>Type 2 diabetes mellitus.</i>	<u><i>i</i></u>		N (NG28)	
	Insulin glargine 300 units in 1mL (Toujeo®)	Hospital initiated/recommended		<i>Type 1 and type 2 diabetes</i>	<u><i>i</i></u>			
	Interferon Alpha	Hospital only		<i>For the treatment of mild chronic hepatitis C.</i>			N (TA106)	
	Isotretinoin (Roaccutane®□)	Hospital only		<i>For the treatment of severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic anti-bacterials and topical therapy.</i>		△		
	Ivabradine (Procoralan®)	Hospital initiated/recommended		<i>Angina</i>				Possibly helpful
	Ivabradine (Procoralan®)	Hospital initiated/recommended		<i>For treating chronic heart failure.</i>			N (TA267)	
L	Lamotrigine (Lamictal®)	Hospital initiated/recommended		<i>Bipolar disorder</i>	<u><i>i</i></u>			
				<i>Treatment to be hospital initiated and stabilised, then GP prescribed.</i>	<u><i>i</i></u>			



A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Lanreotide (Somatuline®)	Shared care	Refer to hospital letter	Acromegaly - fine control of growth hormone levels after surgery/radiotherapy. There is no Shared Care Agreement for Lanreotide and Octreotide because the patient number is very low. However, there is a requirement that the hospital specialists initiating the drug treatment will communicate with patient's GP via a hospital letter regarding prescribing and monitoring.				
	Lanthanum (Fosrenol®)	Hospital only		Hyperphosphataemia in chronic renal failure.	<i>i</i>			Offers an advantage
	Lapatinib (Tyverb®)	Hospital only		See anti-cancer drugs.				
	Leflunomide	Shared care		For use in rheumatology				
	Lenalidomide (Revlimid®)	Hospital only		See anti-cancer drugs.				
	Linacotide (Constella®)	No prescribing		Irritable bowel syndrome with constipation.	<i>i</i>			Judgement reserved
	Linagliptin (Trajenta®▼)	Primary Care		<u>Type 2 diabetes.</u>				
	Liraglutide (Victoza®)	Hospital initiated/recommended		For the treatment of type 2 diabetes mellitus.			N (TA203)	Possibly helpful
	Lisdexamfetamine	Shared care		For Attention Deficit Hyperactivity Disorder (ADHD) in children, young people and adults.			N (NG87)	
	Lithium	Shared care		Bipolar disorder; must prescribe by brand name.				
	Lixisenatide (Lyxumia®▼)	Hospital initiated/recommended		Type 2 diabetes.	<i>i</i>			Judgement reserved
	Lomustine	Hospital only		See anti-cancer drugs.				



A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Lubiprostone (Amitiza®)	Primary Care		<i>For treating chronic idiopathic constipation.</i>			N (TA318)	
	Lurasidone (Latuda®)	Hospital only		Schizophrenia				
	Lysuride	Withdrawn		<i>Dopamine agonist - antiparkinsonian agent.</i>				
M	Melatonin (Circadin®)	No prescribing		<i>Primary insomnia in patients aged 55 years and older.</i>	<i>i</i>			Judgement reserved
	Melatonin (Circadin®)	Shared care		<i>For treatment of sleep disorders in children and adolescents with neurological/neurodevelopmental disorders including attention deficit hyperactivity disorder (ADHD), autism and visual impairment - unlicensed use for all.</i>	<i>i</i>			Offers an advantage
	Melphalan	Hospital only		See anti-cancer drugs.				
	Memantine	Hospital initiated/recommended		<i>For the treatment of Alzheimer's disease.</i> <i>Updated NICE TA 217 states that: non-specialists can now prescribe donezepil, galantamine, rivastigmine and memantine, as long as they have taken advice from a clinician who has the necessary knowledge and skills. This includes:</i> <ul style="list-style-type: none"> • secondary care medical specialists such as psychiatrists, geriatricians and neurologists • other healthcare professionals such as GPs, nurse consultants and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease 	<i>i</i>		N (TA217) N (CG42)	Offers an advantage
	Mercaptopurine	Hospital only		See anti-cancer drugs.				
	6-Mercaptopurine	Shared care	Download	<i>For use in rheumatology, gastroenterology and dermatology.</i>				
	Mesna	Hospital only		See anti-cancer drugs.				

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Methotrexate	Hospital only		Chemotherapy See anti-cancer drugs .				
	Methotrexate tablets and subcutaneous injection (Metoject®)	Shared care	 	<i>Rheumatoid arthritis and other autoimmune diseases, dermatology and gastroenterology</i>				
	Methylnaltrexone (Relistor®)	Hospital only		<i>Opioid induced constipation.</i>	<i><u>i</u></i>			Judgement reserved
	Methylphenidate	Shared care		<i>For Attention Deficit Hyperactivity Disorder (ADHD) in children, young people and adults.</i>			N (NG87)	
	Mesalazine	Hospital initiated/recommended		<i>For inflammatory bowel disease</i>				
	Metolazone	Hospital initiated/recommended		<i>For use in heart failure and fluid overload in renal impairment/failure</i>				
	Midodrine	Hospital initiated/recommended		<i>Postural hypotension in adults.</i>	<i><u>i</u></i>			
	Mirabegron (Betmiga® ▼)	Primary Care		<i>For treating symptoms of overactive bladder.</i>			N (TA290)	
	Mitotane (Lysodren®)	Hospital only		See anti-cancer drugs .				
	Moxifloxacin	Hospital only		<i>Acute exacerbation of chronic bronchitis, community acquired pneumonia (not severe) and acute bacterial sinusitis.</i>	<i><u>i</u></i>			
	Mycophenolate	Hospital only		<i>Transplant immunosuppression for patients initiated after April 2013</i>				
	Mycophenolate	Shared care	Shared care agreement to be provide by transplant centre	<i>Transplant immunosuppression for patients being prescribed in primary care prior to April 2013</i>				











A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
N	Mycophenolate	Shared care		<i>For use in non-transplant adult patients</i>				
	Nalmefene	Hospital only		<i>For reducing alcohol consumption in people with alcohol dependence in conjunction with continuous psychosocial support.</i> Specialist initiation only i.e. Suffolk Turning Point services.	<i><u>i</u></i>		N (TA325)	Possibly helpful
	Naloxegol (Moventiq®)	Hospital initiated/recommended		<i>For treating opioid induced constipation in adults whose constipation has had an inadequate response to laxatives.</i>	<i><u>i</u></i>		N (TA345)	
	Naproxen/esomeprazole (Vimovo®)	No prescribing		<i>Osteoarthritis: Care and management in adults.</i>	<i><u>i</u></i>		N (CG177)	Not acceptable
	Nicorette QuickMist®	Primary Care		<i>To aid smokers wishing to quit or reduce prior to quitting.</i>	<i><u>i</u></i>			
	Nicotinic acid & laropiprant (Tredaptive®)		Withdrawn		<i>All indications.</i>			
O	Nilotinib (Tasigna®)	Hospital only		See anti-cancer drugs.				
	Norgestrel acetate and estradiol hemihydrate (Zoely®)	No prescribing		<i>Oral contraception.</i>	<i><u>i</u></i>			Nothing new
	Ocriplasmin	Hospital only		<i>For treating vitreomacular traction.</i>			N (TA297)	
	Octreotide short-acting and depot preparations (Sandostatin®)	Shared care	Refer to hospital letter	<i>Acromegaly - fine control of growth hormone levels after surgery/radiotherapy.</i> <i>There is no Shared Care Agreement for Lanreotide and Octreotide because the patient number is very low. However, there is a requirement that the hospital specialists initiating the drug treatment will communicate with patient's GP via a hospital letter regarding prescribing and monitoring.</i>				
	Olanzapine (Zyprexa®)	Hospital initiated/recommended		<i>Psychosis and schizophrenia in adults.</i>			N (CG178)	

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
P	Omacor	Hospital only		Secondary prevention of cardiovascular disease and in hypertriglyceridaemia (patients initiated prior to feb 2009 may be continued).	<u><i>i</i></u>			Possibly helpful
	Omalizumab (Xolair®)	Hospital only		Severe allergic asthma in adults and children over 12 years.	<u><i>i</i></u>			
	Omalizumab (Xolair®)	Hospital only		For treating severe persistent allergic asthma (review of TAG 133 and 201).			N (TA278)	
	Ondansetron (Zofran®)	Primary Care		Palliative care (unlicensed indication).	<u><i>i</i></u>			Offers an advantage
	Ondansetron (Zofran®)	Hospital only		Other unlicensed indications.	<u><i>i</i></u>			Offers an advantage
	Ondansetron (Zofran®)	Hospital initiated/recommended		For the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.	<u><i>i</i></u>			
	Ondansetron (Zofran®)	Hospital only		For the prevention and treatment of post operative nausea and vomiting (PONV).	<u><i>i</i></u>			A real advance
	Ondansetron (Zofran®)	Primary Care	Briefing Sheet for Primary Care	Hyperemesis gravidarum (referring to the embedded Briefing Sheet for Primary Care)	<u><i>i</i></u>			
	Oxycodone+naloxone (Targinact®)	Primary Care		Severe pain which can be adequately managed only with opioid analgesics.	<u><i>i</i></u>			Not acceptable
	Paliperidone	Hospital only		Schizophrenia.	<u><i>i</i></u>			Judgement reserved
Paliperidone LA (Xeplion®)	Hospital only		Maintenance treatment of schizophrenia in adult patients.	<u><i>i</i></u>				
Palivizumab (Synagis®)	Hospital only		Prevention of respiratory syncytial virus (RSV) - patient selection as for IMPACT trial.					


A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Penicillamine (Distamine®)	Shared care	Refer to hospital letter	Rheumatoid arthritis and other collagen diseases There is no shared care agreement because the patient number is very low. However, there is a requirement that the hospital specialists initiating the drug treatment will communicate with the patient's GP via a hospital letter regarding prescribing and monitoring				
	Pentoxifylline (Trental®)	No prescribing		For the treatment of intermittent claudication in people with peripheral arterial disease.	<i>i</i>		N (TA223)	
	Pimecrolimus topical (Elidel®)	Hospital initiated/recommended		For atopic eczema.	<i>i</i>		N (TA82)	
	Pramipexole (Mirapexin®)	Hospital initiated/recommended		Restless leg syndrome.	<i>i</i>			Possibly helpful
	Prasugrel (Efient®)	Hospital initiated/recommended		For the treatment of acute coronary syndromes with percutaneous coronary intervention.	<i>i</i>		N (TA182)	Offers an advantage
	Pregabalin (Lyrica®)	Hospital initiated/recommended		As adjunctive therapy in adults with partial seizures with or without secondary generalisation.				Possibly helpful
	Pregabalin (Lyrica®)	Primary Care		Neuropathic pain.	<i>i</i>			Possibly helpful
	Pregabalin (Lyrica®)	Hospital initiated/recommended		Generalised anxiety disorder.	<i>i</i>			Possibly helpful
	Procarbazine	Hospital only		See anti-cancer drugs.				
	Prucalopride (Resolor®)	Hospital initiated/recommended		For the treatment of chronic constipation in women. Note: Prucalopride is now licensed in both men and women.	<i>i</i>		N (TA211)	Judgement reserved
R	Racecadotril (Hidrasec®)	No prescribing		Acute diarrhoea in adults and children.	<i>i</i>			Nothing new
	Ramelteon	Withdrawn		Primary insomnia				Judgement reserved





A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Ranolazine (Ranexa®)	Hospital initiated/recommended		<i>Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).</i>	<i><u>i</u></i>			Judgement reserved
	Rasagiline (Azilect®)	Hospital initiated/recommended		<i>Parkinson's disease</i>	<i><u>i</u></i>			Nothing new
	Retigabine (Trobal® ▼)	Hospital initiated/recommended		<i>For the adjunctive treatment of partial onset seizures in epilepsy.</i>	<i><u>i</u></i>		N (TA232)	Not assessed
	Ribavirin in combination with interferon alpha (Copegus® Rebetol® Virazole®)	Hospital only		<i>For the treatment of mild chronic hepatitis C.</i>			N (TA106)	
	Rifaximin (Targaxan®)	Hospital initiated/recommended		<i>Hepatic encephalopathy</i>	<i><u>i</u></i>			Offers an advantage
	Riluzole (Rilutek®)	Shared care	under development	<i>For the treatment of motor neurone disease.</i>			N (TA20)	
	Rimonabant	Withdrawn		<i>Obesity</i>				Not acceptable
	Risperidone oral (Risperdal®)	Hospital initiated/recommended		<i>Schizophrenia</i>				
	Risperidone sustained release injection (Risperdal Consta®)	Hospital only		<i>Protocol for LHPT patients: it should be initiated by a consultant, the efficacy would be monitored for 3 months and the medication withdrawn if no positive outcome noted, it should only be administered by LHPT staff and would be prescribed and issued by the Trust.</i>				
	Rivaroxaban (Xarelto®)	Hospital only		<i>For the prevention of venous thromboembolism after total hip or total knee replacement in adults.</i>			N (TA170)	
	Rivaroxaban (Xarelto®)	Primary Care		<i>For the prevention of stroke and systemic embolism in people with atrial fibrillation.</i>	<i><u>i</u></i>		N (TA256)	Possibly helpful
	Rivaroxaban (Xarelto®)	Hospital initiated/recommended		<i>For the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism</i>			N (TA261)	

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Rivaroxaban (Xarelto®)	Hospital initiated/recommended		For treating pulmonary embolism and preventing recurrent venous thromboembolism.			N (TA287)	
	Rivaroxaban (Xarelto®)	Hospital initiated/recommended		For preventing adverse outcomes after acute management of acute coronary syndrome.			N (TA335)	
	Rivastigmine	Hospital initiated/recommended		For the treatment of Alzheimer's disease. Updated NICE TA 217 states that: non-specialists can now prescribe donepezil, galantamine, rivastigmine and memantine, as long as they have taken advice from a clinician who has the necessary knowledge and skills. This includes: <ul style="list-style-type: none"> • secondary care medical specialists such as psychiatrists, geriatricians and neurologists • other healthcare professionals such as GPs, nurse consultants and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease 	<i>i</i>		N (TA217) N (CG42)	
	Roflumilast (Daxas®▼)	No prescribing		For the management of severe chronic obstructive pulmonary disease.	<i>i</i>		N (TA244)	Judgement reserved
	Ropinirole	Hospital initiated/recommended		Dopamine agonist - antiparkinsonian agent.				
	Ropinirole	Hospital initiated/recommended		Restless leg syndrome.	<i>i</i>			
	Rotigotine (Neupro®)	Hospital initiated/recommended		Parkinson's disease for patients who cannot swallow.				Possibly helpful
S	Sacubitril valsartan (Entresto®)	Shared care		Symptomatic chronic heart failure with reduced ejection fraction	<i>i</i>		N (TA388)	
	Saxagliptin	Primary Care		Type 2 diabetes.				
	Semaglutide(Ozempic®)	Hospital initiated/recommended	PIL	Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise	<i>i</i>			
	Semaglutide (Rybelsus® □)	Primary Care	Primary Care Information Sheet	For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise	<i>i</i>			

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
	Seretide 500 Accuhaler	Primary Care		<i>In chronic obstructive pulmonary disease.</i>	<i>i</i>			
	Sertindole	Withdrawn		Schizophrenia				
	Sevelamer	Shared care		<i>Hyperphosphataemia in chronic renal failure.</i>	<i>i</i>			
	Sildenafil			See erectile dysfunction.				
	Sirolimus (Rapamune®)	Shared care		<i>Immunosuppression in liver and kidney allograft recipients.</i>				
	Sitagliptin (Januvia®)	Primary Care		<i>Type 2 diabetes</i>	<i>i</i>			Offers an advantage
	Sitagliptin/metformin (Janumet®)	Primary Care		<i>Type 2 diabetes</i>				
	Sodium oxybate (Xyrem®)	Shared care		<i>Cataplexy in narcolepsy.</i>	<i>i</i>			Offers an advantage
	Sodium valproate	Hospital initiated/recommended		<i>Mood stabilisation in bipolar disorder NB: This is an unlicensed use for some preparations of sodium valproate – refer to Summary of Product Characteristics.</i> <i>Treatment to be hospital initiated and stabilised, then GP prescribed.</i>	<i>i</i>			
	Solifenacin (Vesicare®)	Primary Care		<i>Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.</i>	<i>i</i>			
	Somatropin	Shared care		<i>For the treatment of growth failure in children.</i>			N (TA188)	
	Somatropin	Shared care		<i>In adults with growth hormone deficiency.</i>			N (TA64)	

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
I	Sorafenib (Nexavar®)	Hospital only		See anti-cancer drugs.				
	Strontium ranelate (Protelos®▼)	Hospital initiated/recommended		For the secondary prevention of osteoporotic fragility fractures in postmenopausal women.	<i>i</i>		N (TA161)	
	Sulfasalazine	Shared care		For use in rheumatology and gastroenterology				
	Sunitinib (Sutent®)	Hospital only		See anti-cancer drugs.				
	Symbicort® 200/6 or 400/12	Primary Care		Symptomatic treatment of patients with severe COPD (FEV ₁ < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.	<i>i</i>			
	Tacrolimus	Shared care		Immunosuppression in liver and kidney allograft recipients; must prescribe by brand name.				
	Tacrolimus topical ointment (Protopic®)	Hospital initiated/recommended		For atopic eczema.	<i>i</i>		N (TA82)	
	Tadalafil (Cialis®)	No prescribing		Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males (5mg tablets only).	<i>i</i>			Possibly helpful
	Tadalafil (Cialis®)			See erectile dysfunction				
	Tamsulosin/Solifenacin (Vesomni®)	Hospital initiated/recommended		Treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.	<i>i</i>			
	Tapentadol (Palexia®)	No prescribing		Relief of moderate to severe acute pain in adults, which can be adequately managed only with opioid analgesics.	<i>i</i>			Judgement reserved
	Tapentadol SR (Palexia SR®)	Hospital initiated/recommended		Management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics. Can only be initiated by pain specialists using the agreed proforma.				Judgement reserved

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
U	Tapentadol SR (Palexia SR®)	No prescribing		Management of severe chronic pain in palliative care.				
	Tegafur with Uracil (Uftoral®)	Withdrawn		See anti-cancer drugs.				
	Temozolomide	Hospital only		See anti-cancer drugs.				
	Teriparatide (Forsteo®)	Hospital only		For the secondary prevention of osteoporotic fragility fractures in postmenopausal women.	<i>i</i>		N (TA161)	
	Thalidomide (Thalidomide Pharmion®)	Hospital only		See anti-cancer drugs.				
	Ticagrelor (Brilique®)	Hospital initiated/recommended		For the treatment of acute coronary syndromes.			N (TA236)	
	Tioguanine	Hospital only		See anti-cancer drugs.				
	Tolvaptan (Samsca®)	No prescribing		Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).	<i>i</i>			Not acceptable
	Topotecan	Hospital only		See anti-cancer drugs.				
	Treasulfan	Hospital only		See anti-cancer drugs.				
	Tretinoin	Hospital only		See anti-cancer drugs.				
	Ulipristal (ellaOne®)	Primary Care		Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse (UPI) or contraceptive failure.	<i>i</i>			Offers an advantage
	Ulipristal (Esmya®)	Hospital initiated/recommended		Indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The duration of treatment is limited to 3 months - the hospital will supply the 1st 28 days of treatment.	<i>i</i>			Offers an advantage

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
V	Ulipristal (Esmya®)	Hospital initiated/recommended		Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age				
	Ustekinumab (stelara®)	Hospital only		Moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA.	<i>i</i>			
	Valproate semisodium (Depakote®)	Hospital initiated/recommended		Acute hypomania within bipolar disorder, mood stabilisation in bipolar disorder Treatment to be hospital initiated and stabilised, then GP prescribed	<i>i</i>			
	Valsartan & Amlodipine (Exforge®)	Primary Care		Expected to be for use as an antihypertensive in patients whose BP is not adequately controlled on amlodipine or valsartan monotherapy and as replacement for patients taking amlodipine and valsartan.	<i>i</i>			
	Varenicline (Champix®▼)	Primary Care		For smoking cessation.	<i>i</i>		N (TA123)	Possibly helpful
	Vildagliptin (Galvus®)	Primary Care		Type 2 diabetes.	<i>i</i>			Nothing new
	Vildagliptin/metformin (Eucreas®)	Primary Care		Type 2 diabetes.				
	Vinorelbine (Navelbine®)	Hospital only		See anti-cancer drugs.				
	Vitamin D analogues	Primary Care		Management of vitamin D deficiency.				
	Vortioxetine (Brintellix®)	Hospital initiated/recommended		For treating major depressive episodes, where the current episode has not responded to two antidepressants .	<i>i</i>		N (TA367)	
W	Warfarin	Hospital initiated/recommended		Anticoagulant (phlebotomy and monitoring to be carried out by hospital).				
X	Ximelagatran	Withdrawn		Prevention of venous thrombosis after hip and knee surgery.				

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
<u>Z</u>	Zonisamide (Zonegran®)	Hospital initiated/recommended		Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.	<i>i</i>			Possibly helpful

Traffic Light Rating:

- **DOUBLE RED:** Not recommended for prescribing by either primary or secondary care.
- **RED:** Not recommended for prescribing by primary care, prescribing responsibility to be retained in secondary care for Hospital Only Prescribing.
- **AMBER:** Initiated by specialist in secondary care, prescribing can be continued in primary care in conjunction with a Shared Care Agreement.
- **GREEN:** Initiated (if clinically urgent) or advised (if non-urgent) by specialist in secondary care, prescribing can be continued in primary care (shared care not required, but GP should be provided with sufficient information).
- **BLUE:** For routine prescribing in primary and secondary care.
- **GREY:** Withdrawn from use

*Shared Care - means that there is either an agreed shared document which has been submitted to the Suffolk D&TC or the consultant and GP have discussed the individual treatment plan for a specific patient. Thus where a decision is defined as AMBER, it is in effect RED until either a document has been produced or a discussion about an individual patient has taken place. The Suffolk D&TC will act as arbiter if necessary.

Prescriber rating:

Bravo!	The drug is a major therapeutic advance in an area where previously no treatment was available
A real advance	The product is an important therapeutic innovation but has certain limitations
Offers an advantage	The product has some value but does not fundamentally change present therapeutics practice
Possibly helpful	The product has minimal additional value, and should not change prescribing habits except in rare circumstances
Judgement reserved	The committee postpones its judgement until better data and a more thorough evaluation of the drug are available
Nothing new	The product may be new substance but is superfluous because it does not add to the clinical possibilities offered by previous products available. In most cases these are "me-too" products

A-Z	Drug or therapy area links to electronic Medicines Compendium eMC	Decision	Shared care agreements, pathways, checklists and briefing sheets	Indication	Rationale	Safety	NICE Guidance (N) or Evidence Summary (ES)	Prescriber rating
-----	---	----------	--	------------	-----------	--------	--	----------------------

Not acceptable

Product without evident benefit over others but with potential or real disadvantages

Not assessed

Links:

[→ Link: Unlicensed medicines & indications guidance](#)